(HealthDay)—For patients with non-small cell lung cancer (NSCLC), smoking cessation after diagnosis is associated with a reduced risk for all-cause mortality, cancer-specific mortality, and disease progression, according ...
Jul 27, 2021
0
1
(HealthDay)—For patients with advanced, chemotherapy-pretreated, immune checkpoint inhibitor-naive squamous (Sq) non-small cell lung cancer (NSCLC), ipilimumab added to nivolumab does not improve outcomes versus nivolumab ...
Jul 16, 2021
0
1
Cancer cells have an uncanny ability to evolve and adapt to overcome the treatments used against them.
Jun 18, 2021
0
16
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated ...
Jun 4, 2021
0
1
Adding sintilimab to a regimen of gemcitabine and platinum demonstrates clinical benefit over gemcitabine and platinum alone as first-line therapy in patients with locally advanced or metastatic squamous cell non-small cell ...
May 25, 2021
0
1
Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy—an abnormal number of chromosomes—tend to respond better to immune checkpoint inhibitor drugs than patients with higher ...
Apr 11, 2021
0
17
(HealthDay)—For patients with advanced squamous non-small cell lung cancer (sq- NSCLC), adding tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS), according to a study ...
Apr 5, 2021
0
2
Patients with a high number of genes most associated with pathways that lead to cell death in lung cancer are at increased risk of dying early from their disease, researchers report.
Apr 5, 2021
0
10
Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. ...
Jan 31, 2021
0
3
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than pembrolizumab alone as first-line therapy for metastatic non-small cell lung cancer (NSCLC) for patients with a PD-L1 ...
Jan 30, 2021
0
3
